微创食管切除术质量控制之齐鲁实践

doi:10.6040/j.issn.1671-7554.0.2021.0855

摘要/Abstract

摘要： 我国食管癌发病率居世界首位,防治工作十分严峻。外科手术仍是“可切除食管癌患者”的最佳治疗方式,随着医学技术的不断进步,微创食管切除术(MIE)逐渐代替传统的开放食管切除术(OE)。MIE较OE显著降低了手术创伤和应激,降低了术后并发症,提高了患者的生活质量,但在改善患者预后方面,MIE与OE的治疗效果尚存在争议。山东大学齐鲁医院胸外科在国内较早开展了MIE及相关的质量控制工作,在MIE过程中实行规范化和标准化,避免过度和不足医疗。论文通过对山东大学齐鲁医院胸外科MIE质量控制的临床实践进行概括总结,期望为国内外的胸外科同行提供参考。

关键词: 微创, 食管切除术, 质量控制

Abstract: The incidence of esophageal cancer in China ranks first in the world, which calls for arduous efforts in its prevention and treatment. Surgery remains the best treatment for patients with “resectable esophageal cancer.” With the progress of medical technology, minimally invasive esophagectomy(MIE)has gradually replaced the traditional open esophagectomy(OE). Compared with OE, MIE significantly reduces surgical trauma, stress and postoperative complications, and improves patients’ quality of life, but the efficacy of MIE and OE in improving the prognoses of patients is still controversial. The Department of Thoracic Surgery of Qilu Hospital of Shandong University carried out MIE and related quality control work earlier in China, and implemented normalization and standardization to avoid excessive and insufficient medical treatment. This paper summarizes our clinical practice of MIE quality control, expecting to provide reference for counterparts in thoracic surgery.

Key words: Minimally invasive, Esophagectomy, Quality control

中图分类号:

R653

田辉,李树海,李林,亓磊,鲁铭,程传乐. 微创食管切除术质量控制之齐鲁实践[J]. 山东大学学报 (医学版), 2021, 59(9): 78-82.

TIAN Hui, LI Shuhai, LI Lin, QI Lei, LU Ming, CHENG Chuanle. Quality control of minimally invasive esophagectomy in Qilu Hospital[J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 78-82.

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma [J]. Gastroenterology, 2018, 154(2): 360-373.
[3] Chen W, Xia C, Zheng R, et al. Disparities by Province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment [J]. Lancet Glob Health, 2019, 7(2): 257-269.
[4] Yoshida N, Yamamoto H, Baba H, et al. Can minimally invasive esophagectomy replace open esophagectomy for esophageal cancer? latest analysis of 24,233 esophagectomies from the japanese national clinical database [J]. Ann Surg, 2020, 272(1): 118-124.
[5] Mann C, Berlth F, Hadzijusufovic E, et al. Minimally invasive esophagectomy: clinical evidence and surgical techniques [J]. Langenbecks Arch Surg, 2020, 405(8): 1061-1067.
[6] Kar M, Imaduddin M, Muduly DK, et al. Minimally invasive esophagectomy: Preservation of arch of Azygos vein in prone position [J]. J Minim Access Surg, 2021, 17(3): 405-407.
[7] 李树海, 岳韦名, 李林, 等. 胸腹腔镜联合食管癌切除术后颈部残胃闭锁端瘘的诊治经验 [J].中华胸部外科电子杂志, 2016, 3(1): 56-58.
[8] Tian Y, Li L, Li S, et al. Comparison of circular stapling, triangulating stapling and T-shape stapling for cervical anastomosis with minimally invasive esophagectomy [J]. Ann Transl Med, 2020, 8(24): 1679.
[9] Takeuchi H, Miyata H, Ozawa S, et al. Comparison of short-term outcomes between open and minimally invasive esophagectomy for esophageal cancer using a nationwide database in Japan [J]. Ann Surg Oncol, 2017, 24(7): 1821-1827.
[10] van der Sluis PC, Schizas D, Liakakos T, et al. Minimally Invasive Esophagectomy [J]. Dig Surg, 2020, 37(2): 93-100.
[11] Sakamoto T, Fujiogi M, Matsui H, et al. Comparing perioperative mortality and morbidity of minimally invasive esophagectomy versus open esophagectomy for esophageal cancer: a nationwide retrospective analysis [J]. Ann Surg, 2021, 274(2): 324-330.
[12] Straatman J, van der Wielen N, Cuesta MA, et al. Minimally invasive versus open esophageal resection: three-year follow-up of the previously reported randomized controlled trial: the time trial [J]. Ann Surg, 2017, 266(2): 232-236.
[13] Weksler B, Sullivan JL. Survival after esophagectomy: a propensity-matched study of different surgical approaches [J]. Ann Thorac Surg, 2017, 104(4): 1138-1146.
[14] Mariette C, Markar SR, Dabakuyo-Yonli TS, et al. Hybrid minimally invasive esophagectomy for esophageal cancer [J]. N Engl J Med, 2019, 380(2): 152-162.
[15] Klevebro F, Kauppila JH, Markar S, et al. Health-related quality of life following total minimally invasive, hybrid minimally invasive or open oesophagectomy: a population-based cohort study [J]. Br J Surg, 2021, 108(6): 702-708.
[16] Yamashita K, Watanabe M, Mine S, et al. Minimally invasive esophagectomy attenuates the postoperative inflammatory response and improves survival compared with open esophagectomy in patients with esophageal cancer: a propensity score matched analysis [J]. Surg Endosc, 2018, 32(11): 4443-4450.
[17] Worrell SG, Bachman KC, Sarode AL, et al. Minimally invasive esophagectomy is associated with superior survival, lymphadenectomy and surgical margins: propensity matched analysis of the National Cancer Database [J]. Dis Esophagus, 2020, 33(10): 17.
[18] Gottlieb-Vedi E, Kauppila JH, Mattsson F, et al. Long-term survival in esophageal cancer after minimally invasive esophagectomy compared to open esophagectomy [J]. Ann Surg, 2021. doi: 10.1097/SLA.0000000000004645.
[19] Samson P, Puri V, Broderick S, et al. Adhering to quality measures in esophagectomy is associated with improved survival in all stages of esophageal cancer [J]. Ann Thorac Surg, 2017, 103(4): 1101-1108.
[20] Adhia A, Feinglass J, Schlick CJ, et al. Adherence to quality measures improves survival in esophageal cancer in a retrospective cohort study of the national cancer database from 2004 to 2016 [J]. J Thorac Dis, 2020, 12(10): 5446-5459.
[21] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14(CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries [J]. Lancet, 2018, 391(10125): 1023-1075.
[22] 孙振国, 岳韦名, 高存, 等. 胸腔镜肺癌手术的质量控制[J]. 中华腔镜外科杂志(电子版), 2020, 13(6): 332-336.
[23] Hermanek P, Wittekind C. The pathologist and the residual tumor(R)classification [J]. Pathol Res Pract, 1994, 190(2): 115-123.
[24] 袁立功, 毛友生. 食管癌环周切缘阳性对预测食管癌预后的研究现状[J]. 中华肿瘤杂志, 2019, 41(4): 241-245. YUAN Ligong, MAO Yousheng. Current status of prognostic evaluation of esophageal cancer patients by circumferential resection margin [J]. Chinese Journal of Oncology, 2019, 41(4): 241-245.
[25] 范俊利, 张卫国. 食管癌切缘阳性治疗现状及进展[J]. 食管疾病, 2020, 2(3): 197-199. FAN Junli,ZHANG Weiguo. Current status and progress of surgical margin positive treatment for esophageal cancer [J]. Journal of Esophageal Diseases, 2020, 2(3): 197-199.
[26] Cai W, Li Y, Huang B, et al. Esophageal cancer lymph node metastasis-associated gene signature optimizes overall survival prediction of esophageal cancer [J]. J Cell Biochem, 2019, 120(1): 592-600.
[27] 亓磊, 田辉, 李林, 等. 微创食管癌切除术后淋巴结转移规律及预后分析[J]. 中华腔镜外科杂志(电子版), 2018, 11(2): 98-102. QI Lei, TIAN Hui, LI Lin, et al. Clinicopathological features of lymph node metastasis and prognostic factors in esophageal cancer treated with minimally invasive esophagectomy [J]. Chinese journal of laparoscopic surgery(Electronic Edition), 2018, 11(2): 98-102.
[28] Visser E, Markar SR, Ruurda JP, et al. Prognostic value of lymph node yield on overall survival in esophageal cancer patients: a systematic review and meta-analysis [J]. Ann Surg, 2019, 269(2): 261-268.
[29] 叶鑫, 赵彦, 游宾, 等. 食管癌根治术胸部淋巴结清扫中国专家共识(2017版)解读[J]. 中华胃肠外科杂志, 2018, 21(9): 976-982. YE Xin, ZHAO Yan, YOU Bin, et al. The interpretation of the Chinese expert consensus on mediastinal lymph node dissection in esophagectomy for esophageal cancer(2017 edition)[J]. Chinese Journal of Gastrointestinal Surgery, 2018, 21(9): 976-982.
[30] Mariette C, Dahan L, Mornex F, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901 [J]. J Clin Oncol, 2014, 32(23): 2416-2422.
[31] Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus(neocrtec5010): a phase iii multicenter, randomized, open-label clinical trial [J]. J Clin Oncol, 2018, 36(27): 2796-2803.
[32] Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis [J]. Lancet Oncol, 2011, 12(7): 681-692.
[33] Alsina M, Moehler M, Lorenzen S. immunotherapy of esophageal cancer: current status, many trials and innovative strategies [J]. Oncol Res Treat, 2018, 41(5): 266-271.
[34] Kelly RJ. The emerging role of immunotherapy for esophageal cancer [J]. Curr Opin Gastroenterol, 2019, 35(4): 337-343.
[35] Schizas D, Charalampakis N, Kole C, et al. Immunotherapy for esophageal cancer: a 2019 update [J]. Immunotherapy, 2020, 12(3): 203-218.
[36] 李树海, 田辉, 岳韦名, 等. ERAS理念指导下VATS肺癌根治术流程优化之齐鲁实践 [J]. 中华腔镜外科杂志(电子版), 2020, 13(3): 145-148.
[37] 吕龙飞, 李林, 李树海, 等. 腔镜下细针导管空肠造瘘在微创McKeown食管癌切除术中的应用 [J]. 山东大学学报(医学版), 2020, 58(7): 77-81. LYU Longfei, LI Lin, LI Shuhai, et al. Application of laparoscopic fine needle catheter jejunostomy in minimally invasive McKeown resection of esophageal cancer [J]. Journal of Shandong University(Health Sciences), 2020, 58(7): 77-81.
[38] Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer [J]. N Engl J Med, 2018, 379(20): 1895-1904.
[39] Melamed A, Margul DJ, Chen L, et al. Survival after minimally invasive radical hysterectomy for early-stage cervical cancer [J]. N Engl J Med, 2018, 379(20): 1905-1914.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed